Drug usage and costs of inpatients with asthma in Karamay Central Hospital in 2014_Chinese Journal of Evidence-Based Medicine

Authors：

WANG Fei ¹ , YU Jiajie ² ,  ZHANG Weidong ¹ ,  LI Youping ² , WU Min ¹ , XU Ting ³ , LIU Jianhong ¹ , LU Jing ³ , ZHANG Shengzhao ¹ , SUN Xin ² , SU Guanyue ²

1. Department of Pharmacy, Karamay Central Hospital, Karamay, 834000, P.R.China;
2. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
3. Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding?author：

ZHANG Weidong, Email: 0990end@sohu.com.cn; LI Youping, Email: yzmylab@hotmail.com

Keywords：

Inpatients; Single disease; Asthma; Evidence-based pharmacy; Rational drug use; Antibiotics; Glucocorticoids

DOI：

10.7507/1672-2531.201611092

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate drug usage and costs of inpatients with asthma in Karamay Central Hospital in 2014 and to provide baseline for evidence-based pharmacy study of single disease in respiratory system. Methods The information of drug use and expenditure of asthma inpatients were collected from the hospital information system (HIS). We analyzed the data including frequency, proportion and cumulative proportion by Excel 2007 software. Results A total of 150 asthma inpatients were included, the average age was 56.25±18.83 years old. Three kinds of the most commonly used drugs were corticosteroids, antibiotics and antiasthmatic drugs. Budesonide suspension for inhalation, moxifloxacin needle, doxofylline needle accounted for 32.84%, 31.11% and 45.31% in these three categories of drugs, respectively. Conclusion The mainly drugs for treatment of asthma inpatients in Karamay Central Hospital in 2014 are corticosteroids, antibiotics and antiasthmatic drugs. The frequency of systemic corticosteroids is too high, and the frequency of antimicrobial use is irrational, which needs further specification.

Citation： WANG Fei, YU Jiajie, ZHANG Weidong, LI Youping, WU Min, XU Ting, LIU Jianhong, LU Jing, ZHANG Shengzhao, SUN Xin, SU Guanyue. Drug usage and costs of inpatients with asthma in Karamay Central Hospital in 2014. Chinese Journal of Evidence-Based Medicine, 2017, 17(8): 884-887. doi: 10.7507/1672-2531.201611092 Copy

1.	GINA. Global strategy for asthma management and prevention. 2016. Avialble at: http://www.ginasthma.org/.
2.	Aumann I, Prenzler A, Welte T, et al. Epidemiology and costs of asthma in Germany: a systematic literature review. Pneumologie, 2014, 68(8): 557-567.
3.	張衛東, 喻佳潔, 劉建紅, 等. 克拉瑪依市中心醫院2014年住院患者呼吸系統疾病構成和費用分析. 中國循證醫學雜志, 2017, 17(5): 507-510.
4.	Ohta K, Ichinose M, Nagase H, et al. Japanese Guideline for Adult Asthma 2014. Allergol Int, 2014, 63(3): 293-333.
5.	國家衛生和計劃生育委員會. 2014 年醫院出院病人疾病. 中國衛生和計劃生育統計年鑒, 2015: 144-147.
6.	張承杰, 湯淑琴, 林艷. 為抵御重特大疾病風險構建防線-基于新疆油田建立企業補充醫療保險的實踐. 中國醫療保險, 2013, (8): 24-26.
7.	GINA. Global strategy for asthma management and prevention. 2014. Avialble at: http://www.ginasthma.org/.
8.	Perpina TM, Garcia RF, Alvarez Gutierrez FJ, et al. Guidelines for the study of nonspecific bronchial hyperresponsiveness in asthma. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol, 2013, 49(10): 432-446.
9.	Agarwal R, Dhooria S, Aggarwal AN, et al. Guidelines for diagnosis and management of bronchial asthma: joint recommendations of national college of chest physicians (India) and Indian chest society. Indian J Chest Dis Allied Sci, 2015, 57(Spec): 5-52.
10.	Society BT. British guideline on the management of asthma. Thorax, 2014, 69(Suppl 1): 1-192.
11.	Kim DK, Park YB, Oh YM, et al. Korean asthma guideline 2014: summary of major updates to the Korean asthma guideline 2014. Tuberc Respir Dis, 2016, 79(3): 111-120.
12.	Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43(2): 343-373.
13.	中華醫學會呼吸病學分會哮喘學組. 中國支氣管哮喘防治指南(基層版). 中華結核和呼吸雜志, 2013, 36(5): 331-336.
14.	蒙忠. 支氣管哮喘合并肺部感染 1 例的藥學監護. 臨床合理用藥雜志, 2015, 8(4): 164-165.
15.	Smits HH, Hiemstra PS, Prazeres da CC, et al. Microbes and asthma: opportunities for intervention. J Allergy Clin Immunol, 2016, 137(3): 690-697.
16.	程遠雄, 趙波, 張慶. 臨床藥師用藥教育對患者哮喘控制的作用. 醫藥導報, 2015, 34(5): 685-686.
17.	馬明華, 薛冬梅, 田薇薇, 等. 臨床藥師開展哮喘規范化管理的成效分析. 中國藥師, 2014, 17(7): 1194-1197.
18.	Yao T, Sung HY, Mao Z, et al. The healthcare costs of secondhand smoke exposure in rural China. Tob Control, 2015, 24(3): 221-226.

1. GINA. Global strategy for asthma management and prevention. 2016. Avialble at: http://www.ginasthma.org/.
2. Aumann I, Prenzler A, Welte T, et al. Epidemiology and costs of asthma in Germany: a systematic literature review. Pneumologie, 2014, 68(8): 557-567.
3. 張衛東, 喻佳潔, 劉建紅, 等. 克拉瑪依市中心醫院2014年住院患者呼吸系統疾病構成和費用分析. 中國循證醫學雜志, 2017, 17(5): 507-510.
4. Ohta K, Ichinose M, Nagase H, et al. Japanese Guideline for Adult Asthma 2014. Allergol Int, 2014, 63(3): 293-333.
5. 國家衛生和計劃生育委員會. 2014 年醫院出院病人疾病. 中國衛生和計劃生育統計年鑒, 2015: 144-147.
6. 張承杰, 湯淑琴, 林艷. 為抵御重特大疾病風險構建防線-基于新疆油田建立企業補充醫療保險的實踐. 中國醫療保險, 2013, (8): 24-26.
7. GINA. Global strategy for asthma management and prevention. 2014. Avialble at: http://www.ginasthma.org/.
8. Perpina TM, Garcia RF, Alvarez Gutierrez FJ, et al. Guidelines for the study of nonspecific bronchial hyperresponsiveness in asthma. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol, 2013, 49(10): 432-446.
9. Agarwal R, Dhooria S, Aggarwal AN, et al. Guidelines for diagnosis and management of bronchial asthma: joint recommendations of national college of chest physicians (India) and Indian chest society. Indian J Chest Dis Allied Sci, 2015, 57(Spec): 5-52.
10. Society BT. British guideline on the management of asthma. Thorax, 2014, 69(Suppl 1): 1-192.
11. Kim DK, Park YB, Oh YM, et al. Korean asthma guideline 2014: summary of major updates to the Korean asthma guideline 2014. Tuberc Respir Dis, 2016, 79(3): 111-120.
12. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43(2): 343-373.
13. 中華醫學會呼吸病學分會哮喘學組. 中國支氣管哮喘防治指南(基層版). 中華結核和呼吸雜志, 2013, 36(5): 331-336.
14. 蒙忠. 支氣管哮喘合并肺部感染 1 例的藥學監護. 臨床合理用藥雜志, 2015, 8(4): 164-165.
15. Smits HH, Hiemstra PS, Prazeres da CC, et al. Microbes and asthma: opportunities for intervention. J Allergy Clin Immunol, 2016, 137(3): 690-697.
16. 程遠雄, 趙波, 張慶. 臨床藥師用藥教育對患者哮喘控制的作用. 醫藥導報, 2015, 34(5): 685-686.
17. 馬明華, 薛冬梅, 田薇薇, 等. 臨床藥師開展哮喘規范化管理的成效分析. 中國藥師, 2014, 17(7): 1194-1197.
18. Yao T, Sung HY, Mao Z, et al. The healthcare costs of secondhand smoke exposure in rural China. Tob Control, 2015, 24(3): 221-226.

Chinese Journal of Evidence-Based Medicine

Drug usage and costs of inpatients with asthma in Karamay Central Hospital in 2014

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content